Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …

methotrexate
tacrolimus
corticosteroids
prednisone
mycophenolate
  • 103 views
  • 24 Jan, 2021
  • 27 locations
25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti

adjuvant therapy
vascular endothelial growth factor
type 2 diabetes mellitus
vitreous hemorrhage
visual loss
  • 5 views
  • 22 Jan, 2021
  • 1 location
Validation of Standardized Test Protocols to Assess the Impact of Visual Pathologies in Daily Life Activities

conditions but also in virtual reality (VR). This tool can be used to measure a therapeutic benefit for new treatments (like gene therapy, retinal implants, intra vitreous injections ) for visual loss

retinopathy
gene therapy
other disease
retinal degeneration
  • 0 views
  • 24 Jan, 2021
  • 1 location
Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial

the venous sinus may improve patients' objective symptoms (such as visual loss and papilledema) and subjective symptoms (such as headache). This study will determine whether dural venous sinus

  • 0 views
  • 25 Jan, 2021
  • 1 location
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

manifestations of Coats' disease. It can be complicated by macular edema due to leakage from microvascular ectasia. When associated with visual loss, macular edema can be treated with different strategies

  • 0 views
  • 29 Jan, 2021
  • 1 location
Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)

untreated or insufficiently treated, scleritis can progress to peripheral ulcerative keratitis, uveitis and glaucoma. Visual loss occurs in approximately 10% of patients with anterior scleritis and in up to

  • 0 views
  • 24 Jan, 2021
  • 1 location
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept

Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (NV AMD), is an important cause of central visual loss, especially among Asian and African

  • 0 views
  • 28 Jan, 2021
  • 1 location
TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration

-retinal neovascular membranes ( new blood vessels) develop beneath the retina. The new vessels can leak causing haemorrhage that leads to significant visual loss. Photodynamic therapy ( PDT) is

fibrosis
neovascularization
visual loss
macular degeneration
photodynamic therapy
  • 19 views
  • 07 Nov, 2020
  • 1 location
Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Type 3 neovascularization is a subtype of neovascular age-related macular degeneration (AMD) that is characterized by intraretinal neovascularization. Treat-and-extend (TAE) regimen is a widely-used, effective anti-vascular endothelial growth factor treatment regimen for neovascular AMD, regardless of subtypes of AMD. The purpose of the present study is to investigate the 18-month …

  • 0 views
  • 04 Mar, 2021
  • 1 location
Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure

The purpose of this study is to evaluate the vision and posterior segment of eyes in children and young adults less than 22 years of age with risk, suspicion, or past medical history significant for elevated intracranial pressure (ICP). Patients will have visual acuity and color vision tested. Assessment of …

  • 8 views
  • 26 Jan, 2021
  • 1 location